Adagio Medical Holdings, Inc. (ADGM): Submission of Matters to a Vote of Security Holders

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 23, 2026, Adagio Medical Holdings, Inc.’s (the “Company”) held a Special Meeting of Stockholders (the “Special Meeting”). The stockholders considered one proposal which is described in more detail in the Co

Original reporting
Published Oct 26, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 26, 2026, 12:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$ADGM
Neutral
high confidence
Mentioned
$ADGM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ADGMNeutralMed
01

Why it matters

The approved reverse split may pressure the stock as the share count will be reduced, potentially widening the price per share.

02

Market read

likely pressure as the market prices in the dilution and uncertainty of the split ratio.

03

Timing

immediate

Relevance 6/10Novelty 8/10Timing: immediate
Company-level read

Ticker impact

$ADGMNeutralHigh confidence
Context

SEC 8‑K reports shareholder approval of a reverse stock split (1‑for‑10 to 1‑for‑500) for Adagio Medical Holdings.

Expected impact

likely pressure as the market prices in the dilution and uncertainty of the split ratio.

Evidence & confidence

Reverse splits often trigger short‑term volatility; the wide ratio range adds uncertainty.

Related articles

$ADGMMed

Adagio Medical treats 22 patients in ventricular ablation study

Adagio Medical (ADGM) treated 22 patients with its vCLAS Ultra system in a study across the U.S. and Canada. The FULCRUM-VT trial, evaluating the system's safety and effectiveness, enrolled 209 patients. Doctors reported over 60% reduction in ablation times. The company is also reviewing strategic alternatives and submitted a PMA application for its first-generation system to the FDA in May 2026.

$ADGMMedAI 8/10

Orange County Business Journal

Adagio Medical announced study results for its vClas Ultra cryoablation system, with the first patient treated by Dr. Roderick Tung. The study aims to support FDA approval for the first-generation device. Shares of Adagio (ADGM) were trading at 47 cents with a market cap of $10.6 million.

$ADGMMedAI 8/10

Adagio Medical Highlights First Patient Treated in IDE Study Evaluating Next-Generation vCLAS™ Ultra System for Ventricular Tachycardia at Banner – University Medical Center Phoenix

Adagio Medical (ADGM) announced the first patient treated in its IDE study for the next-gen vCLAS Ultra System, designed for ventricular tachycardia (VT). The study aims to support a PMA supplement for the FDA. The system showed improved maneuverability and reduced ablation time in pre-clinical data. The company is focused on demonstrating the system's potential for faster, more efficient VT ablation procedures.

$ADGMMed

Adagio Medical Reports Second Quarter 2026 Results

Adagio Medical Holdings, Inc. (ADGM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Adagio Medical Reports Second Quarter 2026 Results LAGUNA HILLS, CA, August 11, 2026 – Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today anno

$ADGMMedAI 8/10

Adagio Medical Treats First Patient With Next-Generation VCLAS Ultra System; Stock Up

Adagio Medical Holdings (ADGM) said it treated its first patient with its next-generation vCLAS Ultra ultra-low temperature ablation system under FDA expanded access. The patient with non-ischemic cardiomyopathy and prior failed VT ablations was treated at the University of Pennsylvania. Adagio also noted IDE approval for its FULCRUM-VT trial and reported no VT recurrence two months later.